Why Semaglutide Makes Food Less Enjoyable — And Why the Effect Fades Over Time
Dopamine neurons that control pleasure eating actively fight against semaglutide's appetite suppression, explaining both why GLP-1 drugs reduce food enjoyment and why some patients develop tolerance.
Quick Facts
What This Study Found
Researchers discovered the neural circuit that drives hedonic eating — consuming palatable food purely for pleasure, not hunger. A specific pathway from the peri-locus ceruleus to VTA dopamine neurons controls this behavior: these neurons encode how tasty food is and drive continued consumption.
Critically for the GLP-1 drug field, semaglutide initially suppressed these dopamine neurons during food consumption, but mice developed tolerance — recovering both their palatable food appetite and dopamine neuron activity during repeated semaglutide treatment. When researchers artificially inhibited these dopamine neurons during eating, the tolerance was reversed. This reveals that the dopamine pleasure system actively fights against semaglutide's appetite-suppressing effects.
Key Numbers
Peri-locus ceruleus → VTA dopamine pathway identified · VTADA neurons encode palatability · Semaglutide suppresses VTADA responsiveness · Tolerance develops with repeated dosing · VTADA inhibition reverses tolerance
How They Did This
The researchers used photometry-calibrated optogenetics — a cutting-edge technique that uses light to precisely control and measure individual neuron activity in living mice. They identified the neural pathway from the peri-locus ceruleus to VTA dopamine (VTADA) neurons, measured how these neurons respond to palatable food, tested the effect of semaglutide on this circuit, and then manipulated VTADA neuron activity to determine if it could reverse semaglutide tolerance.
Why This Research Matters
This Science paper answers two major questions about GLP-1 drugs. First, it explains WHY semaglutide reduces the pleasure of eating — it suppresses the dopamine neurons that encode food palatability. Second, and perhaps more importantly, it reveals a mechanism for weight loss plateau and potential regain: the dopamine system adapts to fight back against the drug's appetite suppression. Understanding this opponent process could lead to combination therapies that prevent tolerance to GLP-1 agonists.
The Bigger Picture
Published in Science, this is one of the most important mechanistic studies explaining how GLP-1 drugs affect the brain's reward system. The finding that the dopamine system actively opposes semaglutide's effects has enormous implications: it suggests that the weight loss plateaus many patients experience aren't just about metabolic adaptation — the brain's pleasure circuitry is literally fighting back. This opens a clear therapeutic strategy: combining GLP-1 drugs with agents that modulate the dopamine reward pathway to prevent tolerance.
What This Study Doesn't Tell Us
This is a mouse study — the specific neural circuits and their behavior may not perfectly translate to human brain physiology. The optogenetic manipulation used artificial stimulation/inhibition that doesn't replicate natural neural activity patterns. The semaglutide dosing regimen in mice may not reflect human pharmacokinetics or treatment duration. Human hedonic eating involves psychological and social factors beyond the dopamine circuit described here.
Questions This Raises
- ?Could adding a dopamine-modulating drug to semaglutide prevent the tolerance that causes weight loss plateaus in humans?
- ?Is this same dopamine tolerance mechanism responsible for the reports of food 'noise' returning after months on GLP-1 drugs?
- ?Do different GLP-1 agonists (tirzepatide, liraglutide) produce different levels of dopamine suppression and tolerance?
Trust & Context
- Key Stat:
- Tolerance Dopamine neurons recovered their activity during repeated semaglutide treatment, restoring palatable food appetite — but this was reversed when the neurons were artificially inhibited
- Evidence Grade:
- Moderate-High evidence from a rigorous neuroscience study published in Science using state-of-the-art optogenetic techniques. The causal manipulation of specific neural circuits provides strong mechanistic evidence. Rated below 'Strong' because it's a mouse study and translation to human neurobiology requires confirmation.
- Study Age:
- Published in 2025, this is a brand-new study that will likely reshape understanding of how GLP-1 drugs interact with the brain's reward system and inform the next generation of obesity combination therapies.
- Original Title:
- Hedonic eating is controlled by dopamine neurons that oppose GLP-1R satiety.
- Published In:
- Science (New York, N.Y.), 387(6741), eadt0773 (2025)
- Authors:
- Zhu, Zhenggang, Gong, Rong, Rodriguez, Vicente, Quach, Kathleen T, Chen, Xinyu, Sternson, Scott M
- Database ID:
- RPEP-14656
Evidence Hierarchy
Frequently Asked Questions
Is this why food becomes boring on Ozempic/Wegovy?
Yes — this study provides a direct neural explanation. Semaglutide suppresses the dopamine neurons that encode how tasty food is, literally reducing the brain's pleasure response to eating. Many patients describe this as 'food noise' disappearing or food simply not being interesting anymore. This study shows it's not psychological — it's the drug suppressing specific reward neurons.
Does this explain why weight loss plateaus on GLP-1 drugs?
Partially, yes. The study found that with repeated semaglutide treatment, the dopamine neurons recover their activity and mice regain their appetite for palatable food. If the same happens in humans, it would mean the brain's reward system gradually overcomes the drug's appetite-suppressing effect — one mechanism that could contribute to the well-known weight loss plateau.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-14656APA
Zhu, Zhenggang; Gong, Rong; Rodriguez, Vicente; Quach, Kathleen T; Chen, Xinyu; Sternson, Scott M. (2025). Hedonic eating is controlled by dopamine neurons that oppose GLP-1R satiety.. Science (New York, N.Y.), 387(6741), eadt0773. https://doi.org/10.1126/science.adt0773
MLA
Zhu, Zhenggang, et al. "Hedonic eating is controlled by dopamine neurons that oppose GLP-1R satiety.." Science (New York, 2025. https://doi.org/10.1126/science.adt0773
RethinkPeptides
RethinkPeptides Research Database. "Hedonic eating is controlled by dopamine neurons that oppose..." RPEP-14656. Retrieved from https://rethinkpeptides.com/research/zhu-2025-hedonic-eating-is-controlled
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.